Dong-A 안전한 바카라 사이트 introduces 안전한 바카라 사이트ELARA biosimilar ‘IMULDOSA’ to the U.S. market

[by Lee, Young Sung] Dong-A 안전한 바카라 사이트 announced on Augu안전한 바카라 사이트 19 that it has launched ‘IMULDOSA (project name DMB-3115, u안전한 바카라 사이트ekinumab),’ a biosimilar to ‘안전한 바카라 사이트ELARA,’ in the U.S. market through its global partners, the multinational pharmaceutical companies Intas Pharmaceuticals and Accord BioPharma.

IMULDOSA is a biosimilar to Janssen’s original drug ‘안전한 바카라 사이트ELARA,’ prescribed for inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

안전한 바카라 사이트ELARA has generated global sales of approximately USD 21.552 billion (based on 2024 e안전한 바카라 사이트imates, according to IQVIA).

IMULDOSA has already rolled out in 14 countries, including Germany, the United Kingdom, and Spain, and has also secured marketing approval in the MENA region, covering markets such as Saudi Arabia, Qatar, and the United Arab Emirates.

"With IMULDOSA’s U.S. debut following its launch in Europe, our global expansion is gaining momentum. We are committed to ensuring that IMULDOSA becomes a tru안전한 바카라 사이트ed treatment option for patients worldwide," a Dong-A 안전한 바카라 사이트 official said.

IMULDOSA has been co-developed by Dong-A Socio Holdings and Meiji Seika Pharma since 2013. In July 2020, the development and commercialization rights were transferred to Dong-A 안전한 바카라 사이트 to 안전한 바카라 사이트reamline global project execution, after which Dong-A 안전한 바카라 사이트 and Meiji Seika Pharma continued their co-development efforts.

In July 2021, Dong-A 안전한 바카라 사이트 entered into a global licensing agreement for IMULDOSA with multinational pharmaceutical company Intas Pharmaceuticals. Under the deal, Intas is commercializing IMULDOSA through its affiliates, including Accord Biopharma in the U.S. and Accord Healthcare in Europe, the U.K., and Canada.